Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BCAB
BCAB logo

BCAB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Bioatla Inc (BCAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
4.080
1 Day change
-10.92%
52 Week Range
71.500
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BCAB is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks positive catalysts, has no recent news support, shows bearish institutional flow, and does not have a strong proprietary buy signal. With no clear financial improvement data and a weak forward pattern bias, the better decision is to avoid buying now.

Technical Analysis

BCAB is showing a mixed-to-weak short-term setup. MACD histogram is positive and expanding at 0.112, which is constructive, but RSI_6 at 72.118 is elevated and suggests the move is stretched rather than a clean entry. Moving averages are converging, which points to an unclear trend rather than a strong breakout. Price at 4.19 is right at resistance R1 4.178 and below R2 4.379, while pivot support is 3.854. The pattern-based trend estimate is bearish, with a 60% chance of -2.14% next day, -3.19% next week, and -9.58% next month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data is extremely thin and uninformative here, with zero put-call imbalance reported and no meaningful volume or open-interest details. Historical volatility is very high at 84.47, which indicates large price swings but does not currently provide a bullish sentiment edge.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
5

Positive Catalysts

  • No recent news was reported, so there are no identified event-driven positive catalysts. Technical momentum is mildly positive via MACD expansion, and the stock is trading near short-term resistance, which could allow a breakout if volume appears later.

Neutral/Negative Catalysts

  • Hedge funds are selling aggressively, with selling up 760.39% over the last quarter. Insiders are neutral with no meaningful buying support. No recent news means no catalyst support, and the proprietary trading signals are absent: AI Stock Picker has no signal today and SwingMax has no recent signal. The pattern-based outlook is negative over the next day, week, and month.

Financial Performance

No usable latest-quarter financial snapshot was available due to an error, so there is no reliable revenue, earnings, or growth read to support a long-term buy case. Because the latest quarter season cannot be confirmed from the provided data, the financial picture remains incomplete and does not justify new investment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a positive Wall Street revision trend. Based on the available information, Wall Street appears neutral-to-cautious rather than bullish, with the main pros being mild technical momentum and the main cons being weak sentiment, no catalyst, and lack of fundamental confirmation.

Wall Street analysts forecast BCAB stock price to rise
2 Analyst Rating
Wall Street analysts forecast BCAB stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.580
sliders
Low
4
Averages
7
High
10
Current: 4.580
sliders
Low
4
Averages
7
High
10
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2025-08-13
Reason
Citizens JMP
Reni Benjamin
Price Target
$NULL
AI Analysis
2025-08-13
downgrade
Outperform -> Market Perform
Reason
Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.

People Also Watch